Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

Model scores of the 29,894 trials active now.

Model score 32% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerpancreaticradiationresectionchemotherapy
  Phrases that lowered it: participantsparticipant40adultml
• Sponsor's past termination rate: 17.9% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 87 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 7.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 279 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 65.0% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 3077 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Primary purpose: supportive care (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 472 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP) NCT01587534 · started 2011 · scored riskier than 94% of active trials completed
• Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy NCT00766636 · started 2008 · scored riskier than 99% of active trials terminated
• Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer NCT02767752 · started 2016 · scored riskier than 88% of active trials terminated
• Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer NCT02243007 · started 2014 · scored riskier than 96% of active trials terminated
• A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma NCT01839799 · started 2013 · scored riskier than 99% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.